PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress
Hayes C, Gallucci G, Boyer J, Assis D, Ghonem N. PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress. Hepatology Communications 2024, 9: e0612. PMID: 39699308, PMCID: PMC11661771, DOI: 10.1097/hc9.0000000000000612.Peer-Reviewed Original ResearchConceptsPeroxisome proliferator-activated receptor agonistsPrimary biliary cholangitisPrimary sclerosing cholangitisPeroxisome proliferator-activated receptorUnited States Food and Drug Administration approvalHepatic accumulation of bile acidsRisk of progression to cirrhosisFood and Drug Administration approvalPeroxisome proliferator-activator receptor agonismSecond-line therapyFirst-line therapySymptoms of cholestasisDrug Administration approvalTreatment of cholestatic liver diseasesCholestatic liver diseaseAccumulation of bile acidsProgression to cirrhosisTreatment of cholestasisSignificant clinical interestSmall bile ductsProliferator-activated receptorsBile acid metabolismIncomplete respondersBiliary cholangitisBiliary stricturesPPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases
Gallucci G, Hayes C, Boyer J, Barbier O, Assis D, Ghonem N. PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases. Cells 2024, 13: 1296. PMID: 39120326, PMCID: PMC11312002, DOI: 10.3390/cells13151296.Peer-Reviewed Original ResearchPrimary biliary cholangitisPrimary sclerosing cholangitisPeroxisome proliferator-activated receptorCholestatic liver diseaseUrsodeoxycholic acidUridine 5'-diphospho-glucuronosyltransferaseObeticholic acidBile acid metabolismAdjunctive therapyIncomplete response to UDCAProgression of primary biliary cholangitisResponse to UDCALiver diseasePeroxisome proliferator-activated receptor agonistsSecond-line treatmentMarkers of cholestasisImpairment of bile flowTherapeutic targetTreatment of cholestatic liver diseasesRetention of bile acidsAlternative treatment strategiesProgression to fibrosisProliferator-activated receptorsAcid metabolismBiliary cholangitis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply